SCHEMBL15328208

SCHEMBL15328208

COc1cc(OC)c2cnc(-c3ccc(Nc4ccc(C)cc4)cc3)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
TP53 P04637 3/20 0.47
SLC2A1 P11166 1/20 0.44
PDGFRB P09619 3/20 0.43
PDGFRA P16234 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
CASP1 P29466 1/20 0.43
HSD17B10 Q99714 1/20 0.43
EGFR P00533 1/20 0.43
ERBB2 P04626 1/20 0.43
ACP1 P24666 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15328263 0.89 PDGFRB (0.54) MAPTTP53PDGFRBPDGFRAMEN1
SCHEMBL15328004 0.85 ABCG2 (0.45) MAPTPDGFRBPDGFRAMEN1KMT2A
SCHEMBL1304390 0.85 PDGFRB (0.51) MAPTPDGFRBPDGFRAMEN1KMT2A
SCHEMBL346309 0.81 PDGFRB (0.50) MAPTPDGFRBPDGFRAMEN1KMT2A
SCHEMBL15533402 0.81 ALDH1A1 (0.48) MAPTTP53SLC2A1PDGFRBPDGFRA
SCHEMBL347611 0.81 ALDH1A1 (0.44) MAPTTP53PDGFRBPDGFRAMEN1
SCHEMBL348341 0.80 PDGFRB (0.67) MAPTPDGFRBPDGFRAMEN1KMT2A
SCHEMBL348350 0.79 CYP1A2 (0.47) MAPTTP53PDGFRBPDGFRAMEN1
SCHEMBL15327931 0.78 ALDH1A1 (0.44) MAPTPDGFRBPDGFRAMEN1KMT2A
SCHEMBL15329423 0.77 TLR8 (0.49) MAPTTP53PDGFRBPDGFRAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 MAPT 1238/4885TP53 254/4885SLC2A1 3331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.